SD BIOTECHNOLOGIES CO., LTD.: debt-to-equity, ROE and more
KOSDAQ, Legal name SD BIOTECHNOLOGIES CO., LTD.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 60.5%
- Equity ratio
- 62.3%
- ROE
- -25.0%
- Op. margin
- -21.0%
- Rev. growth
- -12.8%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 199.1% | 33.4% | -92.2% | -27.9% | n/a |
| FY2022 consolidated | 1,897.5% | 5.0% | -1,552.9% | -44.2% | -25.5% |
| FY2023 consolidated | 68.8% | 59.3% | -13.3% | -29.1% | -49.4% |
| FY2024 consolidated | 103.7% | 49.1% | -49.5% | -26.8% | -26.6% |
| FY2025 consolidated | 60.5% | 62.3% | -25.0% | -21.0% | -12.8% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩124.7B | ₩92.9B | ₩46.9B | ₩34.5B | ₩30.1B |
| Operating profit | -₩34.8B | -₩41.0B | -₩13.7B | -₩9.2B | -₩6.3B |
| Pre-tax income | -₩42.1B | -₩75.0B | -₩10.0B | -₩13.0B | -₩6.8B |
| Net income | -₩45.1B | -₩75.0B | -₩6.0B | -₩14.8B | -₩7.5B |
| Total assets | ₩146.5B | ₩96.4B | ₩76.1B | ₩60.7B | ₩48.0B |
| Total liabilities | ₩97.5B | ₩91.6B | ₩31.0B | ₩30.9B | ₩18.1B |
| Total equity | ₩49.0B | ₩4.8B | ₩45.1B | ₩29.8B | ₩29.9B |
| Paid-in capital | ₩11.2B | ₩20.9B | ₩54.9B | ₩54.9B | ₩21.9B |
| Debt/equity (source value) | 199.1% | 1,897.5% | 68.8% | 103.7% | 60.5% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2008-09-19
- Listed
- 17/03/02
- Employees
- 62
- Auditor
- 안진회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101113971466
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 에스디생명공학Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.